Jean‐François Cantaloube
Research Subjects
Research Interests
Jean‐François Cantaloube has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Francois Jordier
Unité Emergence et coévolution virale, UMR 6578, CNRS—Etablissement Français du Sang Alpes‐Méditerranée, Marseille, France
1 shared publicationFrançoise Bouchardeau
Institut National de Transfusion Sanguine, Paris, France
1 shared publication- Houssam Attoui
UMR1161 Virologie, INRAE, Ecole Nationale Vétérinaire d’Alfort, ANSES, Université Paris-Est, 94700 Maisons-Alfort, France
1 shared publication Marie‐Héléne Elghouzzi
EFS Ile de France, Rungis, France
1 shared publicationPhilippe Biagini
Unité Emergence et coévolution virale, UMR 6578, CNRS—Etablissement Français du Sang Alpes‐Méditerranée, Marseille, France
1 shared publicationPhilippe de Micco
Unité Emergence et coévolution virale, UMR 6578, CNRS—Etablissement Français du Sang Alpes‐Méditerranée, Marseille, France
1 shared publication
Latest Publications
- 21 August 2008
- Published by Wiley in Journal of Medical Virology
- Vol. 80 (10) , 1732-1739
Molecular characterization of genotype 2 and 4 hepatitis C virus isolates in French blood donors
The subtype distribution of 142 genotype 2 and 97 genotype 4 hepatitis C virus (HCV) isolates from the sera of 1,319 volunteer blood donors in France was determined by gene sequencing and by phylogenetic analysis of the NS5B region and E1 envelope. Findings underlined a wide range of subtypes in both genotypes, that is, 20 in HCV‐2 and 11 in HCV‐4. Eighteen of these 31 subtypes had not been defined previously. Some subtypes, that is, 2a, 2b, 2c, 2i, 2k, 4a, and 4d, showed numerous strains while subtypes in donors from West Africa or Central Africa showed an endemic profile with only a few strains. A Bayesian coalescence approach was used to estimate the demographic history of each HCV subtype. The estimated mean dates of the most recent common ancestors (MRCA) were 1,889 (confidence interval (CI), 1,842–1,930) for HCV‐2a, 1,886 (CI, 1,843–1,921) for HCV‐2b, 1,791 (CI, 1,699–1,848) for HCV‐2c, 1,846 (CI, 1,803–1,878) for HCV‐2i, 1,911 (CI, 1,879–1,937) for HCV‐4a, and 1,957 (CI, 1,943–1,967) for HCV‐4d. The period of spread for subtype 2b, 2c, and 2i was between 1900 and 1960 whereas rapid exponential spread for subtype 2a, 4a, and 4d occurred in the 1960s. The inferred histories of population growth indicated that transmission rates differed according to HCV subtype. These results may help to predict the future burden of HCV in France. J. Med. Virol. 80:1732–1739, 2008.
- 21 August 2008
- Published by Wiley in Journal of Medical Virology
- Vol. 80 (10) , 1732-1739
Molecular characterization of genotype 2 and 4 hepatitis C virus isolates in French blood donors
The subtype distribution of 142 genotype 2 and 97 genotype 4 hepatitis C virus (HCV) isolates from the sera of 1,319 volunteer blood donors in France was determined by gene sequencing and by phylogenetic analysis of the NS5B region and E1 envelope. Findings underlined a wide range of subtypes in both genotypes, that is, 20 in HCV‐2 and 11 in HCV‐4. Eighteen of these 31 subtypes had not been defined previously. Some subtypes, that is, 2a, 2b, 2c, 2i, 2k, 4a, and 4d, showed numerous strains while subtypes in donors from West Africa or Central Africa showed an endemic profile with only a few strains. A Bayesian coalescence approach was used to estimate the demographic history of each HCV subtype. The estimated mean dates of the most recent common ancestors (MRCA) were 1,889 (confidence interval (CI), 1,842–1,930) for HCV‐2a, 1,886 (CI, 1,843–1,921) for HCV‐2b, 1,791 (CI, 1,699–1,848) for HCV‐2c, 1,846 (CI, 1,803–1,878) for HCV‐2i, 1,911 (CI, 1,879–1,937) for HCV‐4a, and 1,957 (CI, 1,943–1,967) for HCV‐4d. The period of spread for subtype 2b, 2c, and 2i was between 1900 and 1960 whereas rapid exponential spread for subtype 2a, 4a, and 4d occurred in the 1960s. The inferred histories of population growth indicated that transmission rates differed according to HCV subtype. These results may help to predict the future burden of HCV in France. J. Med. Virol. 80:1732–1739, 2008.